The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 36 (1) , 1-11
- https://doi.org/10.2165/00003088-199936010-00001
Abstract
Extrapolation of animal data to assess pharmacokinetic parameters in humans is an important tool in drug development. Allometric scaling has many proponents, and many different approaches and techniques have been proposed to optimise the prediction of pharmacokinetic parameters from animals to humans. The allometric approach is based on the power function Y = aWb, where the bodyweight of the species is plotted against the pharmacokinetic parameter of interest on a log-log scale. Clearance, volume of distribution and elimination half-life are the 3 most frequently extrapolated pharmacokinetic parameters. Clearance is not predicted very well (error between predicted and observed clearance >30%) using the basic allometric equation in most cases. Thus, several other approaches have been proposed. An early approach was the concept of neoteny, where the clearance is predicted on the basis of species bodyweight and maximum life-span potential. A second approach uses a 2-term power equation based on brain and bodyweight to predict the intrinsic clearance of drugs that are primarily eliminated by phase I oxidative metabolism. Most recently, the use of the product of brain weight and clearance has been proposed. A literature review reveals different degrees of success of improved prediction with the different methods for various drugs. In a comparative study, the determining factor in selecting a method for prediction of clearance was found to be the value of the exponent. Integration of in vitro data into in vivo clearance to improve the predictive performance of clearance has also been suggested. Although there are proponents of using body surface area instead of bodyweight, no advantage has been noted in this approach. It has also been noted that the unbound clearance of a drug cannot be predicted any better than the total body clearance (CL). In general, there is a good correlation between bodyweight and volume of the central compartment (Vc); hence, Vc does not face the same complications as CL. The relationship between elimination half-life (t1/2β) and bodyweight across species results in poor correlation, most probably because of the hybrid nature of this parameter. When a reasonable prediction of CL and Vc is made, t1/2β may be predicted from the equation t1/2β = 0.693Vc/CL.Keywords
This publication has 51 references indexed in Scilit:
- Interspecies Differences and Scaling for the Pharmacokinetics of Xanthine DerivativesJournal of Pharmacy and Pharmacology, 1992
- Remoxipride: pharmacokinetics and effect on plasma prolactin.British Journal of Clinical Pharmacology, 1991
- Extrapolation of animal toxicity to humans: Interspecies comparisons in drug developmentRegulatory Toxicology and Pharmacology, 1990
- PHARMACOKINETIC AND TOXICITY SCALING OF THE ANTITUMOR AGENTS AMSACRINE AND CI-921, A NEW ANALOG, IN MICE, RATS, RABBITS, DOGS, AND HUMANS1990
- Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian speciesJournal of Applied Toxicology, 1989
- CYCLOSPORINE PHARMACOKINETICS IN RATS AND INTERSPECIES COMPARISON IN DOGS, RABBITS, RATS, AND HUMANS1988
- INTERSPECIES COMPARISON OF ACIVICIN PHARMACOKINETICS1988
- Correlation of Unbound Plasma Clearances of Fifteen Extensively Metabolized Drugs Between Humans and RatsPharmaceutical Research, 1988
- LIFE HISTORY VARIATION IN PRIMATESEvolution, 1985
- Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy.1975